Healthcare / BiotechnologyShanghai
$5.05
-0.07 (-1.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $1.7B · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.4B
P/E
18.0x
↓EV/EBITDA
5.8x
↓ROE
11.9%
↑Gross Margin
16.5%
↓Debt/Equity
0.76
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.1%
FCF CAGR
—
FCF margin
-4.7%
FCF / Net income
-0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $15.90B · net income $978.9M · FCF $-746.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $15.90B | $15.90B | $17.33B | $17.37B | $17.49B |
| Net Income | $978.9M | $978.9M | $943.2M | $678.0M | $608.3M |
| EBITDA | $2.15B | $2.15B | $2.19B | $1.89B | $2.65B |
| EPS | 0.59 | 0.59 | 0.57 | 0.41 | 0.51 |
| Gross Margin | 16.5% | 16.5% | 17.2% | 14.0% | 17.6% |
| Operating Margin | 8.1% | 8.1% | 9.4% | 7.1% | 10.6% |
| Net Margin | 6.2% | 6.2% | 5.4% | 3.9% | 3.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.76 | 0.76 | 0.44 | 0.56 | 0.65 |
| Current Ratio | 0.97 | 0.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-746.5M | $-746.5M | $1.76B | $1.65B | $1.21B |
| Returns | |||||
| ROE | 11.9% | 11.9% | 12.0% | 9.0% | 8.8% |
| Valuation | |||||
| P/E | 18.04 | 18.04 | 10.25 | 11.35 | 12.48 |
| EV/EBITDA | 5.78 | 5.78 | 5.19 | 5.55 | 4.15 |
| P/B | 1.02 | 1.02 | 1.23 | 1.02 | 1.10 |
| Growth & Yield | |||||
| Revenue Growth | -8.3% | -8.3% | -0.2% | -0.6% | — |
| EPS Growth | 3.8% | 3.8% | 39.1% | -20.3% | — |
| Dividend Yield | 7.4% | 7.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-8.7%
EPS terminal req.
$0.45
Spread vs growth
12.5%
5Y implied EPS CAGR
-1.6%
EPS terminal req.
$0.54
Spread vs growth
5.4%
10Y implied EPS CAGR
4.0%
EPS terminal req.
$0.87
Spread vs growth
-0.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.9%
Start / end P/E
13.1x → 8.6x
EPS bridge
0.57 → 0.59
Residual
-1.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.